[Form 4] Jazz Pharmaceuticals, Inc. Insider Trading Activity
Laura Hamill, a director of Jazz Pharmaceuticals (JAZZ), reported two related transactions. On 08/07/2025 she was granted 3,507 restricted stock units under the issuer's non-employee directors stock award plan; each unit represents a contingent right to one ordinary share and the units are scheduled to vest in full on July 24, 2026, subject to continued service and plan conditions. On 08/08/2025 she sold 1,805 shares to satisfy tax obligations arising from prior RSU vesting at a reported price of $111.2502 per share. Reported beneficial ownership was 8,738 shares after the grant and 6,933 shares after the sale. These filings reflect routine director compensation and a sell-to-cover tax transaction.
Laura Hamill, membro del consiglio di Jazz Pharmaceuticals (JAZZ), ha comunicato due operazioni correlate. Il 08/07/2025 le sono state assegnate 3,507 unit脿 azionarie vincolate (RSU) nell'ambito del piano di assegnazione per amministratori non dipendenti; ogni unit脿 rappresenta un diritto condizionato a una azione ordinaria e le unit脿 dovrebbero maturare completamente il July 24, 2026, soggette al mantenimento del rapporto di servizio e alle condizioni del piano. Il 08/08/2025 ha venduto 1,805 azioni per soddisfare obblighi fiscali derivanti dal precedente vesting delle RSU, al prezzo dichiarato di $111.2502 per azione. La partecipazione beneficiaria riportata era di 8,738 azioni dopo l'assegnazione e di 6,933 azioni dopo la vendita. Queste comunicazioni riflettono la remunerazione ordinaria di un direttore e una transazione di sell-to-cover per coprire imposte.
Laura Hamill, consejera de Jazz Pharmaceuticals (JAZZ), inform贸 dos operaciones relacionadas. El 08/07/2025 se le otorgaron 3,507 unidades de acciones restringidas (RSU) en virtud del plan de asignaci贸n de acciones para directores no empleados; cada unidad representa un derecho contingente a una acci贸n ordinaria y las unidades est谩n programadas para consolidarse por completo el July 24, 2026, sujeto a la continuidad del servicio y a las condiciones del plan. El 08/08/2025 惫别苍诲颈贸 1,805 acciones para satisfacer obligaciones fiscales derivadas del anterior vesting de RSU, al precio declarado de $111.2502 por acci贸n. La propiedad beneficiaria informada fue de 8,738 acciones tras la concesi贸n y de 6,933 acciones tras la venta. Estas presentaciones reflejan la compensaci贸n habitual de un director y una operaci贸n de sell-to-cover para cubrir impuestos.
Laura Hamill鞚� Jazz Pharmaceuticals (JAZZ)鞚� 鞚挫偓搿滌劀 霊� 瓯挫潣 甏�霠� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 08/07/2025鞐� 氚滍枆靷潣 牍勳瀯鞗� 鞚挫偓 欤检嫕 靾橃棳 鞝滊弰鞐� 霐半澕 3,507臧滌潣 鞝滍暅欤检嫕雼渼(RSU)臧� 攵�鞐悩鞐堨溂氅�, 臧� 雼渼電� 氤错喌欤� 1欤检棎 雽�頃� 鞛犾爼鞝� 甓岆Μ毳� 雮橅儉雮搓碃 頃措嫻 雼渼霌れ潃 瓿勳啀 攴茧 氚� 鞝滊弰 臁瓣贝 於╈”鞚� 鞝勳牅搿� July 24, 2026鞐� 鞝勲秬 甓岆Μ頇曥爼(vesting)霅� 鞓堨爼鞚挫棃鞀惦媹雼�. 08/08/2025鞐愲姅 鞚挫爠 RSU鞚� 甓岆Μ頇曥爼鞙茧 氚滌儩頃� 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 1,805欤�毳� 欤茧嫻 $111.2502鞚� 鞁犼碃臧�搿� 毵る弰頄堨姷雼堧嫟. 氤搓碃霅� 鞁れ 氤挫湢 欤检嫕靾橂姅 攵�鞐� 頉� 8,738欤�, 毵る弰 頉� 6,933欤�鞓�鞀惦媹雼�. 鞚� 氤搓碃靹滊姅 鞚挫偓鞚� 韱奠儊 氤挫垬鞕� 靹戈笀 於╇嫻鞚� 鞙勴暅 毵る弰(sell-to-cover) 瓯半灅毳� 氚橃榿頃╇媹雼�.
Laura Hamill, administratrice de Jazz Pharmaceuticals (JAZZ), a d茅clar茅 deux op茅rations li茅es. Le 08/07/2025 elle a re莽u 3,507 unit茅s d'actions restreintes (RSU) dans le cadre du plan d'attribution d'actions pour administrateurs non salari茅s ; chaque unit茅 repr茅sente un droit conditionnel 脿 une action ordinaire et les unit茅s doivent devenir enti猫rement acquises le July 24, 2026, sous r茅serve de la poursuite du service et des conditions du plan. Le 08/08/2025 elle a vendu 1,805 actions pour couvrir des obligations fiscales d茅coulant de l'acquisition pr茅c茅dente des RSU, au prix d茅clar茅 de $111.2502 par action. La participation b茅n茅ficiaire d茅clar茅e 茅tait de 8,738 actions apr猫s l'attribution et de 6,933 actions apr猫s la vente. Ces d茅clarations refl猫tent la r茅mun茅ration habituelle d'une administratrice et une op茅ration de sell-to-cover visant 脿 couvrir des imp么ts.
Laura Hamill, Direktorin von Jazz Pharmaceuticals (JAZZ), meldete zwei zusammenh盲ngende Transaktionen. Am 08/07/2025 wurden ihr 3,507 Restricted Stock Units (RSU) im Rahmen des Aktienverg眉tungsplans f眉r nicht gesch盲ftsf眉hrende Direktoren gew盲hrt; jede Einheit stellt ein bedingtes Recht auf eine Stammaktie dar, und die Einheiten sollen am July 24, 2026 vollst盲ndig unverfallbar werden, vorbehaltlich fortgesetzter Dienstzeit und der Bedingungen des Plans. Am 08/08/2025 verkaufte sie 1,805 Aktien, um Steuerverpflichtungen aus dem fr眉heren RSU-Vesting zu erf眉llen, zu einem gemeldeten Preis von $111.2502 pro Aktie. Der gemeldete wirtschaftliche Besitz betrug nach der Gew盲hrung 8,738 Aktien und nach dem Verkauf 6,933 Aktien. Diese Meldungen spiegeln die routinem盲脽ige Verg眉tung einer Direktorin und eine Sell-to-Cover-Transaktion zur Steuerabdeckung wider.
- None.
- None.
Insights
TL;DR: Routine director RSU grant and sell-to-cover; no material market impact indicated.
The Form 4 discloses a grant of 3,507 RSUs and a subsequent sale of 1,805 shares at $111.2502 to satisfy taxes. The RSUs are contingent rights to receive ordinary shares and vest on July 24, 2026 if conditions are met. The transactions moved beneficial ownership from 8,738 to 6,933 shares. These actions are standard director compensation mechanics and a routine sell-to-cover; they do not, by themselves, signal operational or financial changes at the company.
TL;DR: Director award aligns incentives through deferred equity; vesting schedule encourages continued service.
The grant of 3,507 restricted stock units under the non-employee directors plan creates deferred equity alignment between the director and shareholders because each unit converts to one share upon vesting. The full vest date is disclosed as July 24, 2026 and is conditioned on continuous service. The sale of 1,805 shares to cover tax liabilities is a typical administrative step following vesting. Governance-wise, these are routine compensation and tax-related transactions rather than governance red flags.
Laura Hamill, membro del consiglio di Jazz Pharmaceuticals (JAZZ), ha comunicato due operazioni correlate. Il 08/07/2025 le sono state assegnate 3,507 unit脿 azionarie vincolate (RSU) nell'ambito del piano di assegnazione per amministratori non dipendenti; ogni unit脿 rappresenta un diritto condizionato a una azione ordinaria e le unit脿 dovrebbero maturare completamente il July 24, 2026, soggette al mantenimento del rapporto di servizio e alle condizioni del piano. Il 08/08/2025 ha venduto 1,805 azioni per soddisfare obblighi fiscali derivanti dal precedente vesting delle RSU, al prezzo dichiarato di $111.2502 per azione. La partecipazione beneficiaria riportata era di 8,738 azioni dopo l'assegnazione e di 6,933 azioni dopo la vendita. Queste comunicazioni riflettono la remunerazione ordinaria di un direttore e una transazione di sell-to-cover per coprire imposte.
Laura Hamill, consejera de Jazz Pharmaceuticals (JAZZ), inform贸 dos operaciones relacionadas. El 08/07/2025 se le otorgaron 3,507 unidades de acciones restringidas (RSU) en virtud del plan de asignaci贸n de acciones para directores no empleados; cada unidad representa un derecho contingente a una acci贸n ordinaria y las unidades est谩n programadas para consolidarse por completo el July 24, 2026, sujeto a la continuidad del servicio y a las condiciones del plan. El 08/08/2025 惫别苍诲颈贸 1,805 acciones para satisfacer obligaciones fiscales derivadas del anterior vesting de RSU, al precio declarado de $111.2502 por acci贸n. La propiedad beneficiaria informada fue de 8,738 acciones tras la concesi贸n y de 6,933 acciones tras la venta. Estas presentaciones reflejan la compensaci贸n habitual de un director y una operaci贸n de sell-to-cover para cubrir impuestos.
Laura Hamill鞚� Jazz Pharmaceuticals (JAZZ)鞚� 鞚挫偓搿滌劀 霊� 瓯挫潣 甏�霠� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 08/07/2025鞐� 氚滍枆靷潣 牍勳瀯鞗� 鞚挫偓 欤检嫕 靾橃棳 鞝滊弰鞐� 霐半澕 3,507臧滌潣 鞝滍暅欤检嫕雼渼(RSU)臧� 攵�鞐悩鞐堨溂氅�, 臧� 雼渼電� 氤错喌欤� 1欤检棎 雽�頃� 鞛犾爼鞝� 甓岆Μ毳� 雮橅儉雮搓碃 頃措嫻 雼渼霌れ潃 瓿勳啀 攴茧 氚� 鞝滊弰 臁瓣贝 於╈”鞚� 鞝勳牅搿� July 24, 2026鞐� 鞝勲秬 甓岆Μ頇曥爼(vesting)霅� 鞓堨爼鞚挫棃鞀惦媹雼�. 08/08/2025鞐愲姅 鞚挫爠 RSU鞚� 甓岆Μ頇曥爼鞙茧 氚滌儩頃� 靹戈笀 鞚橂毳� 於╇嫻頃橁赴 鞙勴暣 1,805欤�毳� 欤茧嫻 $111.2502鞚� 鞁犼碃臧�搿� 毵る弰頄堨姷雼堧嫟. 氤搓碃霅� 鞁れ 氤挫湢 欤检嫕靾橂姅 攵�鞐� 頉� 8,738欤�, 毵る弰 頉� 6,933欤�鞓�鞀惦媹雼�. 鞚� 氤搓碃靹滊姅 鞚挫偓鞚� 韱奠儊 氤挫垬鞕� 靹戈笀 於╇嫻鞚� 鞙勴暅 毵る弰(sell-to-cover) 瓯半灅毳� 氚橃榿頃╇媹雼�.
Laura Hamill, administratrice de Jazz Pharmaceuticals (JAZZ), a d茅clar茅 deux op茅rations li茅es. Le 08/07/2025 elle a re莽u 3,507 unit茅s d'actions restreintes (RSU) dans le cadre du plan d'attribution d'actions pour administrateurs non salari茅s ; chaque unit茅 repr茅sente un droit conditionnel 脿 une action ordinaire et les unit茅s doivent devenir enti猫rement acquises le July 24, 2026, sous r茅serve de la poursuite du service et des conditions du plan. Le 08/08/2025 elle a vendu 1,805 actions pour couvrir des obligations fiscales d茅coulant de l'acquisition pr茅c茅dente des RSU, au prix d茅clar茅 de $111.2502 par action. La participation b茅n茅ficiaire d茅clar茅e 茅tait de 8,738 actions apr猫s l'attribution et de 6,933 actions apr猫s la vente. Ces d茅clarations refl猫tent la r茅mun茅ration habituelle d'une administratrice et une op茅ration de sell-to-cover visant 脿 couvrir des imp么ts.
Laura Hamill, Direktorin von Jazz Pharmaceuticals (JAZZ), meldete zwei zusammenh盲ngende Transaktionen. Am 08/07/2025 wurden ihr 3,507 Restricted Stock Units (RSU) im Rahmen des Aktienverg眉tungsplans f眉r nicht gesch盲ftsf眉hrende Direktoren gew盲hrt; jede Einheit stellt ein bedingtes Recht auf eine Stammaktie dar, und die Einheiten sollen am July 24, 2026 vollst盲ndig unverfallbar werden, vorbehaltlich fortgesetzter Dienstzeit und der Bedingungen des Plans. Am 08/08/2025 verkaufte sie 1,805 Aktien, um Steuerverpflichtungen aus dem fr眉heren RSU-Vesting zu erf眉llen, zu einem gemeldeten Preis von $111.2502 pro Aktie. Der gemeldete wirtschaftliche Besitz betrug nach der Gew盲hrung 8,738 Aktien und nach dem Verkauf 6,933 Aktien. Diese Meldungen spiegeln die routinem盲脽ige Verg眉tung einer Direktorin und eine Sell-to-Cover-Transaktion zur Steuerabdeckung wider.
